touchEXPERT OPINIONS How can the selection of patients with type 1 diabetes suitable for adjunctive treatment with SGLT inhibitors be optimized?

• What is the impact of poor glycaemic control in people with T1D?
• Why do some people with T1D not achieve good glycaemic control?
• What is the ideal profile for an adjunctive therapy to insulin in people with T1D?
• What are SGLT inhibitors and how do they improve glycaemic control?
• Why do people suitable for consideration for adjunctive therapy with an SGLT inhibitor need to have a BMI >27 kg/m²?
• What impact do the SGLT inhibitors have on other microvascular and macrovascular diabetic complications?

Dr Khazrai is a lecturer of Nutrition and Food Sciences at Campus Bio-Medico University, Rome, Italy. She is a dietitian, diabetes educator and person-centred counsellor and performs her clinical work at the outpatient clinic of the University Hospital.

Since 2001, Dr Khazrai has conducted research with the Endocrinology and Diabetes Clinic of the Campus Bio-Medico University and provides counselling for family members of adolescents with T1D. She has also been involved in the TRIGR (Trial to Reduce IDDM in the Genetically at Risk) trial within Italy.

Disclosures: None

• Which patients with T1D should be considered for adjunctive therapy with an SGLT inhibitor?
• What is DKA?
• Why are people with T1D prone to DKA?
• What is the clinical trial evidence for the safety of SGLT inhibitors in people with T1D?
• How can we mitigate the risk of DKA?

Mrs Hicks is a Nurse Consultant, Diabetes, for Medicus Health Partners, Enfield, UK. She is also a founding member and Co-Chair of TREND (Training, Research and Education for Nursing in Diabetes)-UK and Chair of Injection Technique Matters.

Mrs Hicks has worked in diabetes nursing since 1990 and has published over 140 papers in that time. She has been a member of the editorial board of the Journal of Diabetes Nursing since it was first published, and she was the editor-in-chief for over 10 years. She is currently a member of the editorial board of The Diabetes Times.

Disclosures: Debbie Hicks has worked in an advisory capacity and presented for: Boehringer Ingelheim, B Braun, GlucoRx, Lilly, MSD, Mylan, Napp, Novo Nordisk, Owen Mumford, Sanofi andTakeda. She has also accepted sponsorship to attend educational meetings from Lilly. MSD and Novo Nordisk. She is Director of TREND-UK (Diabetes) Ltd and CreativeDiabetes Ltd.